Beraprost-314d Added-on to Tyvaso® (BEAT)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 273 participants.

Also called NCT01908699

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 273 participants (enrolled count) (from the registry)
Sponsor
Lung Biotechnology PBC (from the registry)
Registry
  • NCT NCT01908699
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Israel (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01908699. Randomized; triple masking; primary purpose treatment. Start 2013-05-31 (actual); primary completion 2019-02-19 (actual). Results posted on 2020-02-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Beraprost-314d Added-on to Tyvaso® (BEAT)
Acronym
BEAT
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Beraprost Sodium 314d Modified Release Tablets
Intervention (Drug)
Placebo
Lead sponsor
Lung Biotechnology PBC (class: industry)

Record details

Record id
cardio:ct-nct01908699
Content hash
08b0e3f41eb33bef31fa159f971efdf6033cd9df1ec1f89ac09a968822c74f55